Vaccine Safety Monitoring
A vaccine is a biological agent that provides active acquired immunity to a particular disease. A vaccine typically contains a component that seems like a disease-causing microbe and is often made from weakened or killed forms of the microbe, its toxins or one of its surface proteins. Vector is an organism that transfers a pathogen from reservoir to host. Traditional approach of live-attenuated vaccine immunization has resulted in remarkable success in the reduction and control of infectious disease. But many pathogens remain less responsive to the traditional vaccine strategies. Therefore, more appropriate vaccine strategies are needed. Recent discovery on the field of viral molecular biology and genetics has provided the opportunity to use viruses as vaccine platforms and as potential anti-cancer agents. Now-a-days viral vectors are considered as an attractive to the traditional platforms.
An adjuvant is an ingredient of that helps create a stronger immune response in the human body. In short, adjuvants help vaccines work more efficiently. Drug delivery refers to approaches, formulations, and techniques for administering a pharmaceutical compound in the body to safely achieve its desired therapeutic effect. Both the vectors, adjuvants and delivery system are important to get the safe action of a vaccine.
- Quality and Safety of Vaccines
- Mucosal Vaccines, Adjuvants
- DAMP/PAMP Mechanism
- Emulsion Delivery System
- Solid Particulate Vaccine Delivery
- Needle Free Delivery System
- Micro Needle
- Vaccine Acceptability
Related Conference of Vaccine Safety Monitoring
9th International Conference on Vaccines, Immunology and Clinical Trials
7th International conference on Vaccines, Vaccination and Immunization
Vaccine Safety Monitoring Conference Speakers
Recommended Sessions
- Advances in Vaccine Technology
- Biomarkers of Vaccine Adjuvant Potency and Safety
- Human Genetics and Vaccines
- Immunology / Animal Models
- Nanotechnology in Vaccine Delivery System
- Novel Vaccines Against Infectious Diseases
- Vaccine Adjuvants
- Vaccine Adjuvants- FDA & CDC
- Vaccine Delivery
- Vaccine Design, Production and Safety
- Vaccine Development
- Vaccine Safety Monitoring
- Vaccines Adjuvants Market Analysis
- Vaccines Against Infectious Diseases and Cancer
- Veterinary Vaccines and Their Delivery Systems
Related Journals
Are you interested in
- Advancements in Vaccine Research and Development - Vaccines R&D 2026 (France)
- Advances in Pediatric Vaccines - Vaccines R&D 2026 (France)
- Animal & Plant Derived Vaccines - Vaccines-Immunization-2026 (France)
- Animal Models & Clinical Trials - Vaccines-Immunization-2026 (France)
- Antibodies: Engineering & Therapeutics - Vaccines-Immunization-2026 (France)
- Bioinformatics and AI in Vaccine Design - Vaccine Immunology 2026 (France)
- Cancer, Malaria & TB Vaccines - Vaccines-Immunization-2026 (France)
- Cellular Immunology & Latest Innovations - Vaccines-Immunization-2026 (France)
- Challenges in Vaccine Accessibility and Equity - Vaccine Immunology 2026 (France)
- Clinical Trials Design and Methodologies - Vaccines R&D 2026 (France)
- Clinical Vaccinology and Immunotherapy - Vaccine Immunology 2026 (France)
- Combination & Conjugate Vaccines - Vaccines-Immunization-2026 (France)
- Current Research & Future Challenges - Vaccines-Immunization-2026 (France)
- DNA & Synthetic Vaccines - Vaccines-Immunization-2026 (France)
- Emerging Infectious Diseases - Vaccine Immunology 2026 (France)
- Emerging Infectious Diseases and Vaccine Development - Vaccines R&D 2026 (France)
- Ethical Considerations in Vaccine Development and Distribution - Vaccines R&D 2026 (France)
- Fish & Poultry Vaccines - Vaccines-Immunization-2026 (France)
- Future Directions in Vaccine Research - Vaccine Immunology 2026 (France)
- Geriatric Immunization - Vaccines-Immunization-2026 (France)
- Global Immunization Strategies and Policy - Vaccines R&D 2026 (France)
- Global Vaccination Strategies - Vaccine Immunology 2026 (France)
- HIV Vaccines - Vaccines-Immunization-2026 (France)
- Human Microbiome and Vaccines - Vaccine Immunology 2026 (France)
- Immunogenetics and Personalized Vaccines - Vaccine Immunology 2026 (France)
- Immunogenetics and Personalized Vaccines - Vaccine Immunology 2026 (France)
- Immunology and Immune System Innovations - Vaccine Immunology 2026 (France)
- Immunology of Infectious Diseases - Vaccine Immunology 2026 (France)
- Immunology of Infectious Diseases - Vaccines R&D 2026 (France)
- Immunotherapy and Personalized Medicine - Vaccines R&D 2026 (France)
- Immunotherapy and Vaccines for Non-Infectious Diseases - Vaccine Immunology 2026 (France)
- Immunotherapy in Cancer Treatment - Vaccine Immunology 2026 (France)
- Industry and Technology Innovations - Vaccine Immunology 2026 (France)
- Innovations in Vaccine Cold Chain and Storage - Vaccines R&D 2026 (France)
- Maternal, Neonatal, and Geriatric Immunization - Vaccine Immunology 2026 (France)
- Microbiome-Targeted Vaccines - Vaccine Immunology 2026 (France)
- Nanotechnology and Advanced Delivery Systems - Vaccine Immunology 2026 (France)
- Nanotechnology in Vaccine Delivery - Vaccine Immunology 2026 (France)
- Next-Generation Vaccine Platforms - Vaccine Immunology 2026 (France)
- Novel Vaccine Platforms: mRNA, DNA, and Viral Vectors - Vaccine Immunology 2026 (France)
- One Health Approach to Vaccine Development - Vaccine Immunology 2026 (France)
- Paediatric Vaccination - Vaccines-Immunization-2026 (France)
- Pandemic Preparedness and Response - Vaccine Immunology 2026 (France)
- Public Health and Global Immunization - Vaccine Immunology 2026 (France)
- Regulatory Approaches in Vaccine Development - Vaccines R&D 2026 (France)
- Role of Adjuvants in Vaccine Efficacy - Vaccines R&D 2026 (France)
- Role of AI and Big Data in Vaccine Research - Vaccines R&D 2026 (France)
- The Economics of Vaccination - Vaccine Immunology 2026 (France)
- Translational Immunology and Vaccine Development - Vaccines R&D 2026 (France)
- Travel & Edible Vaccines - Vaccines-Immunization-2026 (France)
- Vaccine Delivery Systems: Innovations and Challenges - Vaccines R&D 2026 (France)
- Vaccine Development for Cancer Immunotherapy - Vaccines R&D 2026 (France)
- Vaccine Development for Vector-Borne Diseases - Vaccines R&D 2026 (France)
- Vaccine Equity and Access in Low-Resource Settings - Vaccines R&D 2026 (France)
- Vaccine Hesitancy and Public Perception - Vaccines R&D 2026 (France)
- Vaccine Hesitancy and Public Trust - Vaccine Immunology 2026 (France)
- Vaccine Manufacturing and Distribution - Vaccines R&D 2026 (France)
- Vaccine Production & Development - Vaccines-Immunization-2026 (France)
- Vaccine Production and Global Supply Chains - Vaccine Immunology 2026 (France)
- Vaccine Research and Development - Vaccine Immunology 2026 (France)
- Vaccine Safety and Adverse Event Monitoring - Vaccine Immunology 2026 (France)
- Vaccine Safety and Pharmacovigilance - Vaccines R&D 2026 (France)
- Vaccine Safety, Pharmacovigilance, and Adverse Event Monitoring - Vaccine Immunology 2026 (France)
- Vaccine-Induced Immunity and Duration of Protection - Vaccine Immunology 2026 (France)
- Vaccines - Vaccines-Immunization-2026 (France)
- Vaccines & Autism - Vaccines-Immunization-2026 (France)
- Vaccines against Drugs - Vaccines-Immunization-2026 (France)
- Vaccines against Infectious Diseases - Vaccines-Immunization-2026 (France)
- Vaccines for Immune Mediated Diseases - Vaccines-Immunization-2026 (France)
- Vaccines for Pregnant Women & Neonates - Vaccines-Immunization-2026 (France)
- Vaccines for Unconventional Diseases - Vaccines-Immunization-2026 (France)
- Vectors, Adjuvants & Delivery Systems - Vaccines-Immunization-2026 (France)
